ArticleJournal of biochemical and molecular toxicology2026
Eupatilin Alleviates Acute Myocardial Ischemia-Reperfusion Injury in Rats via the Akt/GSK-3β Pathway by Targeting COXs.
Article in Journal of biochemical and molecular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eupatilin confers cardioprotection against myocardial ischemia-reperfusion injury (MIRI). Cyclooxygenases (COXs) serve as key rate-limiting enzymes for prostaglandin biosynthesis. This study investigated the effects of eupatilin on COXs. H9c2 cells subjected to oxygen-glucose deprivation/reoxygenation (OGD/R) were treated with graded doses of eupatilin, with aspirin serving as the positive control. Cellular reactive oxygen species (ROS), cell viability, and COX1/COX2 protein expression were subsequently detected. In-vivo acute MIRI was established in rats by 30-min ligation of the left anterior descending coronary artery followed by reperfusion. MIRI-modeled rats received eupatilin or aspirin treatment. Cardiac function was evaluated by echocardiography. Levels of prostaglandin E2 (PGE2), thromboxane A2 (TXA2), and cardiac troponin I (cTnI) were quantified by ELISA. Myocardial infarct size was assessed by TTC staining, and collagen deposition was determined by Masson staining. Immunohistochemistry was performed to detect myocardial COX1 and COX2 expression. In OGD/R-injured H9c2 cells, eupatilin dose-dependently restored cell viability and suppressed cellular ROS overproduction. It suppressed OGD/R-induced upregulation of COX1 and COX2 and increased phosphorylation of Akt1 (S473) and GSK-3β (S9). Molecular docking revealed favorable binding affinity between eupatilin and COXs. In MIRI-model rats, deteriorated cardiac function was accompanied by increased PGE2, TXA2 and cTnI, as well as aggravated myocardial infarction and collagen deposition. Eupatilin administration alleviated myocardial injury by counteracting these pathological alterations. Moreover, eupatilin suppressed MIRI-driven COX1/COX2 overexpression and enhanced Akt1-GSK-3β phosphorylation. Eupatilin alleviate acute MIRI via COXs inhibition and activation of the Akt/GSK-3β pathway, providing a theoretical basis for its application against MIRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.